脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展

doi:10.3969/j.issn.1003-9198.2023.02.021

摘要/Abstract

中图分类号:

R 541.4

张越, 李晓庆, 鲁翔. 脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展[J]. 实用老年医学, 2023, 37(2): 191-194.

[1] SANTOSO A, HERIANSYAH T, ROHMAN M S. Phospholipase A2 is an inflammatory predictor in cardiovascular diseases: is there any spacious room to prove the causation?[J]. Curr Cardiol Rev, 2020, 16(1): 3-10.
[2] 胡盛寿, 杨跃进, 郑哲, 等. 中国心血管病报告2018概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
[3] 吴岑岑, 祖凌云, 陈少敏, 等. 急性冠状动脉综合征的发病机制及治疗进展[J]. 中华脑血管病杂志:电子版, 2021, 15(1): 6.
[4] HUANG F, WANG K, SHEN J. Lipoprotein-associated phospholipase A2: the story continues[J]. Med Res Rev, 2020, 40(1): 79-134.
[5] ASANO K, OKAMOTO S, FUKUNAGA K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma[J]. Biochem Biophys Res Commun, 1999, 261(2): 511-514.
[6] STAFFORINI D M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)[J]. Cardiovasc Drugs Ther, 2009, 23(1): 73-83.
[7] MAIOLINO G, BISOGNI V, ROSSITTO G, et al. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications[J]. World J Cardiol, 2015, 7(10): 609-620.
[8] TSELEPIS A, DENTAN C, KARABINA S, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1764-1773.
[9] GUERRA R, ZHAO B, MOOSER V, et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins[J]. J Lipid Res, 1997, 38(11): 2281-2288.
[10] DENNIS E, CAO J, HSU Y, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention[J]. Chem Rev, 2011, 111(10): 6130-6185.
[11] LI J, WANG H, TIAN J, et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J]. Medicine: Baltimore, 2018, 97(28): e11517.
[12] FRAS Z, TRSAN J, BANACH M. On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management[J]. Arch Med Sci, 2021, 17(4): 954-964.
[13] PACKARD C, O’REILLY D, CASLAKE M, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group[J]. N Engl J Med, 2000, 343(16): 1148-1155.
[14] EPPS K C, WILENSKY R L. Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease[J]. J Intern Med, 2011, 269(1): 94-106.
[15] DE MAURI A, VIDALI M, CHIARINOTTI D, et al. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients[J]. J Nephrol, 2019, 32(2): 283-288.
[16] ZHANG H, GAO Y, WU D, et al. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease[J]. BMC Cardiovasc Disord, 2020, 20(1): 295.
[17] WANG R, WANG X, ZHANG E, et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease[J]. Am J Transl Res, 2021, 13(8): 8997-9004.
[18] MOUROUZIS K, SIASOS G, OIKONOMOU E, et al. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis, 2021, 20(1): 12.
[19] MA C, XU Z, WANG S, et al. Change of inflammatory factors in patients with acute coronary syndrome[J]. Chin Med J: Engl, 2018, 131(12): 1444-1449.
[20] LI J, ZHOU Z, NIU X, et al. Lipoprotein-associated phospholipase A2 in cardiac disease: a potential early biomarker of unstable coronary artery disease[J]. Clin Lab, 2020, 66(5). doi: 10.7754/Clin.Lab.2019.190719.
[21] YANG L, WANG H, ZHANG Y, et al. The prognostic value of lipoprotein-associated phospholipase A in the long-term care of patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Clin Appl Thromb Hemost, 2018, 24(5): 822-827.
[22] SHENG G, ZHOU J, ZHANG C, et al. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study[J]. Scott Med J, 2021, 66(4): 178-185.
[23] YIN Y, CHEN Y, XU L, et al. Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention[J]. Int J Cardiol Heart Vasc, 2020, 28: 100541.
[24] SVAROVSKAYA A, TEPLYAKOV A, GUSAKOVA A, et al. Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting[J]. Kardiologiia, 2020, 60(8): 98-105.
[25] SERRUYS P, GARCÍA-GARCÍA H, BUSZMAN P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque[J]. Circulation, 2008, 118(11): 1172-1182.
[26] WILENSKY R, SHI Y, MOHLER E, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J]. Nat Med, 2008, 14(10): 1059-1066.
[27] WHITE H, HELD C, STEWART R, et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med, 2014, 370(18): 1702-1711.
[28] O’DONOGHUE M, BRAUNWALD E, WHITE H, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial[J]. JAMA, 2014, 312(10): 1006-1015.
[29] PRASAD M, LENNON R, BARSNESS G, et al. Chronic inhibition of lipoprotein-associated phospholipase A does not improve coronary endothelial function: a prospective, randomized-controlled trial[J]. Int J Cardiol, 2018, 253: 7-13.
[30] CHOI W, PRASAD M, LENNON R, et al. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study[J]. Coron Artery Dis, 2018, 29(2): 104-113.

脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

Metrics

推荐阅读 10

[1]	顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029.
[2]	徐寿勇, 袁勇. 老年病人开展双低剂量CT冠状动脉造影的可行性研究[J]. 实用老年医学, 2024, 38(10): 1054-1058.
[3]	张晶晶, 祝小霞, 姚春雷, 王玮. 控制营养状态评分与老年冠心病病人合并心力衰竭的相关性研究[J]. 实用老年医学, 2024, 38(7): 697-700.
[4]	查志敏, 刘欢, 王向明, 李秋爽, 郭妍. 心脏瓣膜钙化对老年冠心病病人预后的影响[J]. 实用老年医学, 2024, 38(3): 245-250.
[5]	朱晨晨, 秦海东. 斑块侵蚀在急慢性冠脉综合征发生发展中的作用[J]. 实用老年医学, 2024, 38(3): 308-311.
[6]	章颖, 谢玲, 叶佳琦, 羌文慧, 严晓云, 姜英, 张清. 层粘连蛋白与老年急性心肌梗死病人主要不良心血管事件的相关性[J]. 实用老年医学, 2024, 38(2): 149-151.
[7]	王思佳, 韩旭. 老年稳定性冠心病合并颈动脉斑块中医药治疗研究进展[J]. 实用老年医学, 2023, 37(2): 109-111.
[8]	嵇佳林, 刘晶, 王雪黎, 冯泓琳, 韩旭. 冠心平片治疗冠心病的Meta分析和序贯分析[J]. 实用老年医学, 2023, 37(2): 128-133.
[9]	魏梅, 郭岐峰, 段立楠, 尹亚娟, 刘刚, 郑明奇, 刘永升. 亚临床甲状腺功能减退与老年病人经皮冠状动脉介入治疗术后死亡的相关性研究[J]. 实用老年医学, 2023, 37(2): 138-141.
[10]	姚俊秀, 郭进春, 郝小丹, 李龙心, 杨雪, 王璋. 慢性冠状动脉综合征病人肝细胞生长因子的表达及其诊断价值[J]. 实用老年医学, 2023, 37(2): 173-177.
[11]	吴自强, 丁力, 江亚文, 谢志泉, 王继业, 周培毅, 汪丽丽. 运动训练对老年稳定型心绞痛患者运动耐量的影响[J]. 实用老年医学, 2010, 24(2): 153-155.
[12]	陈建慧, 陈隆典, 李芹, 许欣欣. 幽门螺杆菌感染与冠心病的关系研究[J]. 实用老年医学, 2010, 24(2): 174-175.